Combination of Left Ventricular End-Diastolic Diameter and QRS Duration Strongly Predicts Good Response to and Prognosis of Cardiac Resynchronization Therapy
Table 1
Baseline characteristics.
Characteristics
Total population ()
Responders ()
Nonresponders ()
value
Age (years)
61.22 ± 9.54
61.65 ± 10.39
60.33 ± 7.55
0.473
Sex (female)
31 (30.7%)
19 (27.9%)
12 (36.4%)
0.389
BNP (ng/L)
401 (213–1185)
321 (181.3–1129)
685 (325.5–1230)
0.537
NYHA class
II
21 (20.8%)
15 (22.1%)
6 (18.2%)
0.652
III
60 (59.4%)
40 (58.8%)
20 (60.6%)
0.864
IV
20 (19.8%)
13 (19.1%)
7 (21.2%)
0.804
HF duration (months)
48 (12–72)
30 (12–72)
60 (30–96)
0.192
Hypertension, n (%)
21 (20.8%)
15 (22.1%)
6 (18.2%)
0.652
CRD, n (%)
18 (17.8%)
11 (16.2%)
7 (21.2%)
0.535
ICM, n (%)
17 (16.8%)
12 (17.6%)
5 (15.2%)
0.756
LVEF (%)
29.40 ± 4.42
29.56 ± 4.10
29.08 ± 5.06
0.609
LAD (mm)
44.39 ± 5.48
43.41 ± 5.20
46.43 ± 5.58
0.009
LVEDD (mm)
70.06 ± 7.84
68.68 ± 7.38
72.91 ± 8.12
0.010
MR (cm2)
7.2 (4.5–10.4)
7.2 (4.5–10.4)
7.5 (4.4–10.4)
0.278
QRS duration (ms)
165.30 ± 21.33
171.20 ± 21.56
153.30 ± 15.07
< 0.001
LBBB, n (%)
62 (61.4%)
47 (69.1%)
15 (45.5%)
0.022
Mean follow-up time (months)
23.76 ± 14.48
23.60 ± 14.83
24.09 ± 13.95
0.875
Values are mean ± SD, median (range) or n (%). BNP: brain natriuretic peptide; NYHA: New York Heart Association; HF: heart failure; CRD: chronic renal dysfunction; ICM: ischemic cardiomyopathy; LVEF: left ventricular ejection fraction; LAD: left atrial dimension; LVEDD: left ventricular end-diastolic dimension; MR: mitral regurgitation; LBBB: left bundle branch block.
